This study aimed to assess Oral Health-Related Quality of Life (OHQoL) and satisfaction in patients who had complete denture treatment and were diagnosed with systemic diseases. Eighty edentulous patients using new complete dentures were separated into four groups according to their diseases [diabetes mellitus (DM)/osteoporosis (OP)/hypertension (HP)/healthy (control)]. The groups answered the Turkish version of the United Kingdom-Oral Health-Related Quality of Life (OHQoL-UK) and Visual Analog Scale (VAS) questionnaire four weeks after treatment. OHQoL-UK scores were slightly higher for females regardless of the type of disease. Compared with the control participants (57.95±5.33), the scores of the OHQoL-UK were not significantly different in OP and HP groups except for the DM group (58.7±5.37, 58.9±6.44, 45.3±5.19 respectively). DM was significantly associated with the increase of OHQoL values (p<0.05). Patients in all groups reported significantly higher "physical health" scores than other subdomains of OHQoL-UK, although positive correlations were determined among them. Presence of disease had no relationship to the VAS scores. This study shows that systemic diseases might not affect and predict patients' satisfaction with their complete dentures and OHQoL. DM is an independent risk factor for oral health. Satisfaction with the prosthesis might concern a patient's level of OHQoL.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742902 | PMC |
http://dx.doi.org/10.25122/jml-2021-0277 | DOI Listing |
Cureus
December 2024
Oral and Maxillofacial Surgery, College of Medicine - University of Sulaimani, Sulaymaniyah, IRQ.
Background: Diabetes mellitus, a chronic multi-systemic disease affecting various organs, may negatively influence health-related quality of life (HRQoL) and oral health-related quality of life (OHRQoL). This study aimed to investigate this association in a cross-sectional sample of Iraqi Kurdish diabetic patients.
Methods: Two hundred eighty-five type 2 diabetic patients participated in the survey.
JAMIA Open
February 2025
Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, IN 46202, United States.
Objective: Measurement of health-related social needs (HRSNs) is complex. We sought to develop and validate computable phenotypes (CPs) using structured electronic health record (EHR) data for food insecurity, housing instability, financial insecurity, transportation barriers, and a composite-type measure of these, using human-defined rule-based and machine learning (ML) classifier approaches.
Materials And Methods: We collected HRSN surveys as the reference standard and obtained EHR data from 1550 patients in 3 health systems from 2 states.
J Otol
October 2024
Department of Otolaryngology-Head and Neck Surgery, University of Colorado School of Medicine, Aurora, CO, USA.
Objective: To better understand the clinical phenotype of Ménière's disease (MD), we examined family history, thyroid disorder, migraine, and associated disorders in complaints of people living with MD.
Method: We designed the study as a retrospective and examined data gathered from 912 participants with MD. Their data were originally collected by the Finnish Ménière Federation (FMF).
Neurooncol Pract
February 2025
Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands.
According to the 2021 World Health Organization classification of CNS tumors, gliomas harboring a mutation in isocitrate dehydrogenase (mIDH) are considered a distinct disease entity, typically presenting in adult patients before the age of 50 years. Given their multiyear survival, patients with mIDH glioma are affected by tumor and treatment-related symptoms that can have a large impact on the daily life of both patients and their caregivers for an extended period of time. Selective oral inhibitors of mIDH enzymes have recently joined existing anticancer treatments, including resection, radiotherapy, and chemotherapy, as an additional targeted treatment modality.
View Article and Find Full Text PDFFront Public Health
December 2024
AstraZeneca SpA, Milano Innovation District (MIND), Milano, Italy.
Background: Software as a Medical Device (SaMD) and mobile health (mHealth) applications have revolutionized the healthcare landscape in the areas of remote patient monitoring (RPM) and digital therapeutics (DTx). These technological advancements offer a range of benefits, from improved patient engagement and real-time monitoring, to evidence-based personalized treatment plans, risk prediction, and enhanced clinical outcomes.
Objective: The systematic literature review aims to provide a comprehensive overview of the status of SaMD and mHealth apps, highlight the promising results, and discuss what is the potential of these technologies for improving health outcomes.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!